DSGN Stock Summary and Trading Ideas (Design Therapeutics | NASDAQ:DSGN)

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Design Therapeutics trades on the NASDAQ stock market under the symbol DSGN.

As of March 30, 2026, DSGN stock price declined to $10.37 with 167,458 million shares trading.

DSGN has a beta of 0.71, meaning it tends to be less sensitive to market movements. DSGN has a correlation of 0.03 to the broad based SPY ETF.

DSGN has a market cap of $639.54 million. This is considered a Small Cap stock.

In the last 3 years, DSGN traded as high as $11.23 and as low as $1.94.

The top ETF exchange traded funds that DSGN belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

DSGN has outperformed the market in the last year with a price return of +147.5% while the SPY ETF gained +12.7%. DSGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +7.7% and +2.5%, respectively, while the SPY returned -8.2% and -4.3%, respectively.

DSGN support price is $10.11 and resistance is $10.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DSGN shares will trade within this expected range on the day.